BioNano Genomics Inc vs Intel Corp — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Intel Corp trades at $109.87 (market cap $541.60B). The key difference: Intel Corp is far larger — about 41030.3× BioNano Genomics Inc's market cap, and Intel Corp pays a 2.24% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | INTC | |
|---|---|---|
Market Cap | $13.20M | $541.60B |
Sector | Health | Technology |
52-Week High | $4.92 | $140.94 |
52-Week Low | $1.09 | $19.31 |
Enterprise Value | $15.81M | $553.84B |
Volume | — | 43,552,012 |
Dividend Yield | — | 2.24% |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Intel (INTC) trades at $103.12, down 6.12% today, as the stock faces technical bearish signals despite recent earnings beats. The company shows mixed fundamentals with negative net income margins and high valuation ratios, though operating cash flow remains strong at $9.7 billion. Recent news highlights Intel's $5.7 billion AI investment in Ireland while analysts express caution about near-term challenges in the semiconductor sector.
Intel presents a complex investment case with improving operational trends but persistent profitability challenges. The stock offers potential upside to the $105.48 consensus target but faces headwinds from competitive pressures and high capital expenditures. Key catalysts include AI execution and PC market recovery, while risks include margin compression and debt levels.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →